Prelude Therapeutics
PRLD
70 hedge funds and large institutions have $74M invested in Prelude Therapeutics in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 21 reducing their positions, and 7 closing their positions.
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
15% more funds holding
Funds holding: 61 → 70 (+9)
4.18% more ownership
Funds ownership: 80.6% → 84.79% (+4.2%)
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
5% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 21
43% less capital invested
Capital invested by funds: $129M → $74M (-$55.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
+$4.27M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$4.12M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.66M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$1.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$955K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$3.98M |
| 2 |
DM
Deerfield Management
New York
|
-$1.7M |
| 3 |
SCM
Sio Capital Management
New York
|
-$1.22M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$134K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$84.8K |
PRLD Hedge Fund Activity: Q3 2024 in Review
70 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q3 2024, worth a combined $74M — down 43% from $129M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PRLD positions and 7 closed out — a net gain of 9 holders — while 20 added to existing stakes and 21 trimmed.
The largest buyer was ExodusPoint Capital Management, opening a new position worth an estimated $4.27M. The largest seller was Boxer Capital, cutting an estimated $3.98M.
- 70 institutional investors held Prelude Therapeutics (PRLD) as of Q3 2024, up from 61 in Q2 2024.
- Funds reported $74M of Prelude Therapeutics stock for Q3 2024, down 43% quarter-over-quarter.
- 16 funds opened new Prelude Therapeutics positions in Q3 2024 and 7 closed out, a net change of +9 holders.
- The largest Prelude Therapeutics buyer in Q3 2024 was ExodusPoint Capital Management, an estimated $4.27M added.
- The largest Prelude Therapeutics seller in Q3 2024 was Boxer Capital, an estimated $3.98M sold.
Based on aggregated 13F filings for Q3 2024.